Navigation Links
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Date:5/10/2013

NSI-566, was approved by the FDA to commence a Phase I trial to treat chronic spinal cord injury (cSI). This open-label, multi-site study will enroll up to eight patients with thoracic spinal cord injuries (T2-T12) who have an American Spinal Injury Association AIS-A level of impairment, between one and two years post injury. These patients exhibit no motor or sensory function in the relevant segments at and below the injury, and are considered to be in complete paralysis. Study patients will receive six injections in, or around, the injury site: the first four patients will receive 100,000 cells per injection; the second four patients, 200,000 cells per injection. All NSI-566/cSCI patients will receive post-surgery physical therapy, as well as immunosuppressive therapy, which will be for three months, as tolerated. The trial study period will end six months post-surgery for each patient. The primary objective of the study is to determine the safety and toxicity of NSI-566 for the treatment of paralysis and related symptoms due to cSCI. The secondary objectives are to evaluate graft survival in the transplant site by MRI, as well as the effectiveness of transient immunosuppression.

In January, Neuralstem received issuance of U.S. Patent #8,362,262, Divisional Compositions and Methods of Use, part of the small molecule IP; additionally, issuance of PCT Patent #2337517, Floating Cannula and Method of Use, which is exclusively licensed by Neuralstem, and validated in four European countries: Germany, France, Italy and United Kingdom, for a total of five European patents.

In February, Neuralstem's NSI-566 Phase I Clinical Trial in ALS (amyotrophic lateral sclerosis, or Lou Gehrig 's disease) officially concluded, six months after the final surgery at Emory University Hospital.

In February, Neuralstem granted li
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
2. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
3. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
4. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
5. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
6. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
7. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
8. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
9. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
10. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
11. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014   ... will be a 177-key, 4-star boutique hotel in the heart of ... , Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... first hotel within ATLAS , The ... of standard rooms and suites, a sleek restaurant and bar, a ...
(Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
(Date:7/25/2014)... DUBLIN , July 25, 2014 ... of the "Global Metabolomics Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics ... metabolites. Metabolomics has become a new experimental technique ... and the environmental sciences. Metabolites are small molecules ...
(Date:7/25/2014)... 2014 Lawrence Livermore scientists Charles Westbrook ... list of " The World's Most Influential Scientific Minds ... 3,000 researchers who were identified by analyzing citation data ... published the highest-impact work (2002-2012 and 2012-2013). The two ... combustion modeling . , "This recognition is a great ...
Breaking Biology Technology:Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4
... The Board of Directors of Schering-Plough Corporation (NYSE: SGP ... share. Payment will be made on Aug. 31, 2009, to ... 2009. As of March 31, 2009, there were 1,628,335,093 common ... also declared a quarterly dividend of $3.75 per share on the ...
... BASEL, Switzerland, June 23 Syngenta announced today the successful ... year maturity. The proceeds of the bond will be used ... said: "We have taken advantage of favorable current borrowing conditions ... bond issue is part of our normal funding requirements and ...
... SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials ... products, announced today that the company was recently nominated ... in pediatrics. The company is among three ... device analysts in recognition of the development of REPEL-CV(TM) ...
Cached Biology Technology:Syngenta Issues EUR 500 Million Eurobond 2SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination 2
(Date:7/28/2014)... many of these due to genetic factors. This is ... which reduce an individual,s ability to reproduce, to disappear ... Science that recently appeared in Nature Communications ... it explain the high rates of male fertility problems, ... of genetic diseases and their treatment. , Various ...
(Date:7/27/2014)... survived the asteroid strike that wiped them out if ... history, scientists say. , A fresh study using up-to-date ... to build a new narrative of the prehistoric creatures, ... that in the few million years before a 10km-wide ... environmental upheaval. This included extensive volcanic activity, changing sea ...
(Date:7/27/2014)... RESEARCH UK scientists at Barts Cancer Institute have found ... cancer therapy significantly more effective, according to research published ... Barts Cancer Institute, part of Queen Mary University of ... kinase (FAK), signals the body to repair itself after ... DNA. When the researchers removed FAK from blood vessels ...
Breaking Biology News(10 mins):Mutations from Venus, mutations from Mars 2Dinosaurs fell victim to perfect storm of events, study shows 2New drug target can break down cancer's barrier against treatment 2
... journal Neuron sheds new light onto the unknown ... different senses in the complex circuits formed by molecularly distinct ... Ume University associate professor Paolo Medini. One of the ... cortex of the brain processes and integrates the inputs from ...
... 2013 Based on its recent research on ... Sullivan presents TATAA Biocenter with the 2013 European ... TATAA Biocenter offers an end-to-end range of services ... polymerase chain reaction (qRT-PCR) to nucleic acid extraction ...
... 2013 /PRNewswire-iReach/ -- Jade Holding Group, LLC dba Strax Rejuvenation ... has just announced that Dr. Paul J. Reilly , MD, ... (Photo: http://photos.prnewswire.com/prnh/20130819/MN65951 ) Dr. Reilly, who specializes ... an undergraduate at the University of Miami in Florida ...
Cached Biology News:How brain microcircuits integrate information from different senses 2Frost & Sullivan Recognizes TATAA Biocenter's Complete, Best-in-Class Services for Analyzing Genetic Material 2Frost & Sullivan Recognizes TATAA Biocenter's Complete, Best-in-Class Services for Analyzing Genetic Material 3Frost & Sullivan Recognizes TATAA Biocenter's Complete, Best-in-Class Services for Analyzing Genetic Material 4Frost & Sullivan Recognizes TATAA Biocenter's Complete, Best-in-Class Services for Analyzing Genetic Material 5Dr. Paul J. Reilly, MD, FAAFP, is Named Strax Rejuvenation's Doctor of the Month for August 2Dr. Paul J. Reilly, MD, FAAFP, is Named Strax Rejuvenation's Doctor of the Month for August 3
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... XL cell, wide format, is used for vertical electrophoresis ... gels and requires 1.2 L of running buffer. It ... 2.0 mm IPG conversion kit, which contains accessories for ... sets of IPG clamps, 2 sets of 20 x ...
... the drug discovery process in mind. Due ... Safire is the ideal instrument to bridge ... throughput screening. Safire is a fully modular ... range of high speed detection techniques. In ...
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
Biology Products: